PMID- 38150026
OWN - NLM
STAT- MEDLINE
DCOM- 20240320
LR  - 20240320
IS  - 1432-1076 (Electronic)
IS  - 0340-6199 (Linking)
VI  - 183
IP  - 3
DP  - 2024 Mar
TI  - The impact of the BIOFIRE((R)) Blood Culture Identification 2 Panel on 
      antimicrobial treatment of children with suspected systemic inflammatory response 
      syndrome and sepsis.
PG  - 1353-1360
LID - 10.1007/s00431-023-05381-7 [doi]
AB  - This study aimed to assess the therapeutic effects of implementing the BioFire((R)) 
      Blood Culture Identification 2 (BCID2) Panel (bioMerieux, Marcy l'Etoile, France) 
      in the clinical practice of children with sepsis. This retrospective 
      cross-sectional study included children from 15 days of age to 18 years old with 
      sepsis and of whom the BCID2 Panel was studied from the positive blood culture. 
      If the antimicrobial treatment was changed according to the results of BCID2 
      Panel, it was recorded and re-grouped as targeted antimicrobial therapy, 
      de-escalation of the antimicrobial treatment and shifting to another 
      antimicrobial drug if any antimicrobial resistance was detected. Seven-days and 
      thirty-days mortality rate was recorded. Thirty-two patients with 36 septic 
      episodes with positive BCID2 Panel results were included. The median age was 
      10 months 15 days (ranging from 15 days to 16.5 years). The mean difference 
      between having positive results by the BCID2 Panel and conventional culture 
      methods was 82.2 +/- 45.4 h (ranging from 12.3 to 207 h). Effect of the BCID2 Panel 
      on the antimicrobial treatment was detected in 69.4% of the episodes (n = 25). 
      Glycopeptides were ceased at 6 patients, piperacillin/tazobactam was ceased at 6 
      patients, and cefotaxime was ceased at one patient and de-escalation was achieved 
      in 13 episodes which formed the 36.1% of the initial antimicrobial treatment.  
       Conclusion: The BCID2 Panel had an important impact on the patients care and 
      optimization according to the principles of antimicrobial stewardship. The BCID2 
      Panel may be one of the key items for rapid and accurate diagnosis in children 
      with sepsis. Blood culture is still the mainstay for especially detection of 
      antimicrobial drug resistance, while BCID2 tests had several advantages such as 
      speed and diagnostic accuracy as good as blood culture. What is Known: * The 
      BioFire((R)) Blood Culture Identification 2 (BCID2) Panel (bioMerieux, Marcy 
      l'Etoile, France) is a well-validated assay that allows for the simultaneous 
      identification of 43 nucleic acid targets associated with bloodstream infections 
      within about 1 h. What is New: * BCID2 Panel had a direct impact on the patient's 
      treatment decision at the 69.4% of the sepsis episodes. * The clinicians received 
      the microbiological results 82.2 h earlier with BCID2 panel compared to blood 
      culture methods with antimicrobial resistance and de-escalation of the 
      antimicrobial drugs was achieved at 13 episodes which formed the 36.1% of the 
      initial treatment.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Devrim, Ilker
AU  - Devrim I
AUID- ORCID: 0000-0002-6053-8027
AD  - Department of Pediatric Infectious Diseases, University of Health Sciences Dr. 
      Behcet Uz Children's Hospital, Konak, Izmir, 35210, Turkey.
FAU - Ayhan, Fahri Yuce
AU  - Ayhan FY
AUID- ORCID: 0000-0003-2982-0240
AD  - Department of Medical Microbiology, University of Health Sciences Dr. Behcet Uz 
      Children's Hospital, Izmir, Turkey.
FAU - Kacar, Pelin
AU  - Kacar P
AUID- ORCID: 0000-0002-2669-419X
AD  - Department of Pediatric Infectious Diseases, University of Health Sciences Dr. 
      Behcet Uz Children's Hospital, Konak, Izmir, 35210, Turkey.
FAU - Guner Ozenen, Gizem
AU  - Guner Ozenen G
AUID- ORCID: 0000-0002-9725-7501
AD  - Department of Pediatric Infectious Diseases, University of Health Sciences Dr. 
      Behcet Uz Children's Hospital, Konak, Izmir, 35210, Turkey. gzmguner86@gmail.com.
FAU - Bayram, Arzu
AU  - Bayram A
AUID- ORCID: 0000-0003-0307-8877
AD  - Department of Medical Microbiology, University of Health Sciences Dr. Behcet Uz 
      Children's Hospital, Izmir, Turkey.
FAU - Ergun, Deniz
AU  - Ergun D
AUID- ORCID: 0000-0002-6069-1478
AD  - Department of Pediatric Infectious Diseases, University of Health Sciences Dr. 
      Behcet Uz Children's Hospital, Konak, Izmir, 35210, Turkey.
FAU - Ozbakir, Hincal
AU  - Ozbakir H
AUID- ORCID: 0000-0003-0721-3511
AD  - Department of Pediatric Infectious Diseases, University of Health Sciences Dr. 
      Behcet Uz Children's Hospital, Konak, Izmir, 35210, Turkey.
FAU - Gulderen, Mustafa
AU  - Gulderen M
AUID- ORCID: 0000-0002-2227-1288
AD  - Department of Pediatric Infectious Diseases, University of Health Sciences Dr. 
      Behcet Uz Children's Hospital, Konak, Izmir, 35210, Turkey.
FAU - Yilmaz Celebi, Miray
AU  - Yilmaz Celebi M
AUID- ORCID: 0000-0002-3537-0664
AD  - Department of Pediatric Infectious Diseases, University of Health Sciences Dr. 
      Behcet Uz Children's Hospital, Konak, Izmir, 35210, Turkey.
FAU - Ozer, Arife
AU  - Ozer A
AUID- ORCID: 0000-0001-9232-0084
AD  - Department of Pediatric Infectious Diseases, University of Health Sciences Dr. 
      Behcet Uz Children's Hospital, Konak, Izmir, 35210, Turkey.
FAU - Akaslan Kara, Aybuke
AU  - Akaslan Kara A
AUID- ORCID: 0000-0002-9212-5155
AD  - Department of Pediatric Infectious Diseases, University of Health Sciences Dr. 
      Behcet Uz Children's Hospital, Konak, Izmir, 35210, Turkey.
FAU - Bayram, Nuri
AU  - Bayram N
AUID- ORCID: 0000-0003-1802-2518
AD  - Department of Pediatric Infectious Diseases, University of Health Sciences Dr. 
      Behcet Uz Children's Hospital, Konak, Izmir, 35210, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20231227
PL  - Germany
TA  - Eur J Pediatr
JT  - European journal of pediatrics
JID - 7603873
RN  - 0 (Anti-Infective Agents)
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Child
MH  - Humans
MH  - Infant
MH  - *Bacteremia/diagnosis
MH  - Blood Culture
MH  - Retrospective Studies
MH  - Cross-Sectional Studies
MH  - *Sepsis/diagnosis/drug therapy
MH  - *Anti-Infective Agents/therapeutic use
MH  - Anti-Bacterial Agents/therapeutic use
OTO - NOTNLM
OT  - Antimicrobial stewardship
OT  - Bacteremia
OT  - BioFire(R) Blood Culture Identification 2 (BCID2) Panel
OT  - Blood culture
OT  - Children
OT  - De-escalation
EDAT- 2023/12/27 12:42
MHDA- 2024/03/20 06:45
CRDT- 2023/12/27 11:05
PHST- 2023/10/17 00:00 [received]
PHST- 2023/12/10 00:00 [accepted]
PHST- 2023/12/05 00:00 [revised]
PHST- 2024/03/20 06:45 [medline]
PHST- 2023/12/27 12:42 [pubmed]
PHST- 2023/12/27 11:05 [entrez]
AID - 10.1007/s00431-023-05381-7 [pii]
AID - 10.1007/s00431-023-05381-7 [doi]
PST - ppublish
SO  - Eur J Pediatr. 2024 Mar;183(3):1353-1360. doi: 10.1007/s00431-023-05381-7. Epub 
      2023 Dec 27.